BFNH · XBRL financial data

Bioforce Nanosciences Holdings financial statements, every fiscal year

The same tables from 6 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal years (BFNH's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
General and administrative	81	79	63	49	67	67
Total operating expenses	158,409	502	486	472	490	490
Net income (loss)	(158,409)	(502)	(486)	(472)	(490)	(1,292)
Earnings per share, basic USD per share	—	—	(0.02)	(0.02)	(0.02)	(0.04)
Earnings per share, diluted USD per share	—	—	(0.02)	(0.02)	(0.02)	(0.04)
Weighted average shares, basic thousands of shares	—	—	29,272	29,272	29,272	33,207
Weighted average shares, diluted thousands of shares	—	—	29,272	29,272	29,272	33,207

Fiscal years (BFNH's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Cash and cash equivalents	40	11	1	1	1	1
Total current assets	40	11	1	1	1	1
Total assets	40	11	1	1	1	1
Total current liabilities	400	873	1,348	1,820	2,302	619
Total liabilities	400	873	1,348	1,820	2,302	619
Accumulated deficit	(159,170)	(159,672)	(160,158)	(160,630)	(161,120)	(162,412)
Total stockholders' equity	(360)	(862)	(1,347)	(1,819)	(2,302)	(619)
Total liabilities and equity	40	11	1	1	1	1
Common shares outstanding (cover page) thousands of shares	29,272	29,272	29,272	29,272	33,522	33,522

Fiscal years (BFNH's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Net income (loss)	(158,409)	(502)	(486)	(472)	(490)	(1,292)
Net cash from operating activities	(80)	(78)	(68)	(47)	(61)	(65)
Net cash from financing activities	67	49	58	47	61	65
Net change in cash	(13)	(29)	(10)	(0)	0	(0)

SIC 3826 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 3826 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-K, the year less the first three quarters; for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($K)	Revenue, quarter ($K)	Operating cash flow, quarter ($K)	Shares outstanding	Runway	Quarter
Bioforce Nanosciences Holdings	0.3	not reported	(27)*	33.5M	0.0 quarters	Q2 FY26 10-QJun 30, 2026
Scientific Industries	617	1,470	(904)*	11.9M	5.0 quarters	Q2 FY26 10-QJun 30, 2026
Lifeloc Technologies	908	2,445	(133)*	2.8M	6.8 quarters	Q2 FY26 10-QJun 30, 2026
US Nuclear	67	352	(127)	62.8M	0.5 quarters	Q1 FY26 10-QMar 31, 2026
ASTROTECH	8,387	not reported	(2,288)*	2.0M	5.0 quarters	Q4 FY26 10-KJun 30, 2026
Electro Sensors	10,756	not reported	68	3.5M	—	Q1 FY26 10-QMar 31, 2026
Radnostix	1,196	2,672	(614)*	529.2M	2.0 quarters	Q2 FY26 10-QJun 30, 2026
Syntec Optics Holdings	14,047	8,274	(299)*	40.3M	47.0 quarters	Q2 FY26 10-QJun 30, 2026
Bionano Genomics	3,730	8,171	(4,670)*	11.8M	2.1 quarters	Q2 FY26 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.